“Efficacy, Health-Related Outcomes, and Safety of Ixekizumamb for up to Five Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis”. SKIN The Journal of Cutaneous Medicine, vol. 1, no. 3.1, Oct. 2017, p. s12, https://doi.org/10.25251/skin.1.supp.11.